NESS ZIONA, Israel, Nov. 25, 2008 (GLOBE NEWSWIRE) -- Weizmann Science Park -- Kamada (TASE:KMDA), a biopharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that David Tsur, President, Founder and Chief Executive Officer, will present at the Piper Jaffray 20th Annual "Unplugged" Health Care Conference on Tuesday, December 2, 2008 at 10:30 AM ET. The conference is being held at the New York Palace Hotel in New York City.
About Kamada
Kamada specializes in developing a line of specialty life-saving biopharmaceuticals. The company has recently completed a Phase III clinical trial in the U.S. with its flagship IV AAT indicated for treating Alpha-1 Antitrypsin deficiency and is undergoing advanced stages of development with its next generation AAT for inhaled administration indicated for treating various lung diseases.
For additional information, please visit www.kamada.com.